These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36802692)

  • 1. Lutetium177-Labeled DOTA-Ibandronate: A Novel Radiopharmaceutical for Targeted Treatment of Bone Metastases.
    Wang Q; Yang J; Wang Y; Liu H; Feng Y; Qiu L; Chen Y
    Mol Pharm; 2023 Mar; 20(3):1788-1795. PubMed ID: 36802692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of 68 Ga- or 177 Lu-Labeled DOTA-IBA as a Novel Theranostic Radiopharmaceutical for Bone Metastases : A Phase 0/I Study.
    Qiu L; Wang Y; Liu H; Wang Q; Chen L; Liu L; Wang L; Feng Y; Chen Y
    Clin Nucl Med; 2023 Jun; 48(6):489-496. PubMed ID: 36976706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistribution and dosimetry of
    Li H; Pei W; Yang X; Qu G; Hua Q; Liu L; Wang Y; Xu T; Chen Y
    EJNMMI Res; 2024 Mar; 14(1):30. PubMed ID: 38517637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Absorbed Dose Evaluation of [177Lu]Lu-IBA as a Bone Palliative Candidate.
    Ranjbar H; Pourhabib Z
    Nuklearmedizin; 2021 Oct; 60(5):375-380. PubMed ID: 34102691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation, Characterization, and Preliminary Imaging Study of [
    Xu T; Wang Y; Chen Z; Liu H; Yang S; Liu G; Zhao Y; Fu W; Liu L; Xiang K; Peng D; Chen Y
    Contrast Media Mol Imaging; 2022; 2022():7684076. PubMed ID: 35280705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiolabeling, quality control, biodistribution, and imaging studies of
    Xu Q; Zhang S; Zhao Y; Feng Y; Liu L; Cai L; Zhang W; Huang Z; Wei H; Zhuo L; Chen Y
    J Labelled Comp Radiopharm; 2019 Jan; 62(1):43-51. PubMed ID: 30426535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation, biological characterization and preliminary human imaging studies of
    Wang Y; Wang Q; Chen Z; Yang J; Liu H; Peng D; Lei L; Liu L; Wang L; Xing N; Qiu L; Feng Y; Chen Y
    Front Oncol; 2022; 12():1027792. PubMed ID: 36591490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 177Lu-DOTA-IBA Therapy in Prostate Cancer With Bone Metastases.
    Li H; Xu T; Hua Q; Wang L; Chen Y
    Clin Nucl Med; 2023 Aug; 48(8):740-742. PubMed ID: 37390021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 68 Ga-DOTA-Ibandronic Acid PET/CT in a Patient With Chemotherapy-Induced Salivary Gland Hypofunction.
    Liu Y; Ding H; Zhang T; Chen Y; Huang Z
    Clin Nucl Med; 2024 May; 49(5):470-471. PubMed ID: 38465977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodistribution and Internal Dosimetry of 68 Ga-DOTA-IBA PET Imaging for Patients With Bone Metastases.
    Yang J; Deng J; Fan D; Chen G; Lu Z; Liu H; Mok GSP; Chen Y
    Clin Nucl Med; 2023 Oct; 48(10):847-852. PubMed ID: 37418288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective comparison of
    Xiang F; Zhang Y; Tan X; Yan Y; Liu H; Ma W; Chen Y
    Front Oncol; 2024; 14():1428498. PubMed ID: 39144828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary results of biodistribution and dosimetric analysis of [
    Khawar A; Eppard E; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
    Ann Nucl Med; 2019 Jun; 33(6):404-413. PubMed ID: 30877560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theranostic Agent Targeting Bone Metastasis: A Novel [
    Jin W; Zhao R; Wang R; Choi SR; Ploessl K; Alexoff D; Wu Z; Zhu L; Kung HF
    J Med Chem; 2024 Mar; 67(6):4793-4803. PubMed ID: 38450559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers.
    Xu J; Cai F; Luo Z; Fan W; Dai J; Cui J; Li S; Geng C; Zheng Q; Wang Z; Tang X
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2618-2633. PubMed ID: 35347438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on 177Lu-labeled methylene diphosphonate as potential bone-seeking radiopharmaceutical for bone pain palliation.
    Abbasi IA
    Nucl Med Biol; 2011 Apr; 38(3):417-25. PubMed ID: 21492790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo and in vitro evaluation of
    Zhang J; Wang Z; Liu H; Cai L; Feng Y; Zhou L; Wei H; Xie Y; Chen Y
    Hell J Nucl Med; 2019; 22(2):103-110. PubMed ID: 31273351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate.
    Liu D; Balkin ER; Jia F; Ruthengael VC; Smith CJ; Lewis MR
    Nucl Med Biol; 2015 Sep; 42(9):704-10. PubMed ID: 26081917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flare Phenomenon After 177 Lu-DOTA-IBA Therapy in Bone Metastases of Lung Cancer.
    Hua Q; Wang W; Qu G; Pei W; Chen Y
    Clin Nucl Med; 2024 Aug; 49(8):793-796. PubMed ID: 38886924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Bone Metastases of Breast Cancer With 177 Lu-DOTA-IBA.
    Deng J; Yang J; Cheng Z; Chen Y
    Clin Nucl Med; 2024 Jul; 49(7):659-661. PubMed ID: 38537210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.